CD8A and cancer: A recent landmark study in the field of immunotherapy shows that cancer patients homozygous for at least one HLA class I locus present a restricted and less diversified repertoire of tumor-derived neoantigens to CD8+ T-cells compared to fully heterozygous individuals, defining an immunogenetic configuration that may reduce the chances to respond to checkpoint inhibitors (40).